Dr. Le on Treatment Approaches for Oligometastatic Colorectal Cancer

Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with oligometastatic colorectal cancer (CRC).

The treatment of patients with oligometastatic CRC is evolving, says Le. Historically, clinical trials for patients with oligometastatic disease were limited to those with less than 3 or 4 sites of localized metastases. However, in clinical practice, patients could have more than 4 metastatic sites of disease and still be considered oligometastatic.

In the absence of robust clinical trial data, it’s important to have a multidisciplinary team help determine which patients with oligometastatic disease require more aggressive therapy versus those who don’t, concludes Le.